The Relationship Between Manic Episodes and Serum Endocannabinoid Levels in Bipolar Disorder

OBJECTIVE: Endocannabinoids are involved in biological processes relevant to mood regulation, and altered circulating levels have been reported in bipolar disorder (BD). However, serum endocannabinoid levels have not previously been examined across mania and remission within the same patients and compared with healthy controls. This study evaluated serum palmitoylethanolamide (PEA), oleoylethanolamide (OEA), 2-arachidonoylglycerol (2-AG), anandamide (AEA), and C-reactive protein (CRP) levels in patients with BD during manic episodes and remission and in healthy controls. METHODS: Fifty-one patients diagnosed with BD, manic episode, according to DSM-5-TR criteria, and 49 healthy controls were included. After discharge, 32 patients who attended outpatient follow-up visits were re-evaluated during remission. Serum PEA, OEA, 2-AG, AEA, and CRP levels were measured in all participants. Patients with BD were additionally assessed using the Young Mania Rating Scale, Hamilton Depression Rating Scale, and Positive and Negative Syndrome Scale. RESULTS: Serum PEA and OEA levels were significantly lower during manic episodes than in healthy controls. During remission, serum PEA and OEA levels did not differ significantly from those of healthy controls. In within-patient comparisons between manic episodes and remission, only serum PEA levels were significantly lower during manic episodes. CONCLUSION: This is the first study to assess serum endocannabinoid levels in patients with BD during both manic episodes and remission, together with healthy controls. PEA and OEA levels were significantly lower during mania and returned to values comparable to healthy controls during remission. These findings suggest that endocannabinoid-related mechanisms may have potential as future biomarkers and therapeutic targets in mood regulation.

Authors

Institutions

Publication Details

Journal
The International Journal of Neuropsychopharmacology
Published
2026-11-18
DOI
https://doi.org/10.1093/ijnp/pyag050
Primary Topic
Bipolar Disorder and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Relationship Between Manic Episodes and Serum Endocannabinoid Levels in Bipolar Disorder

Yasemin Görgülü, Ruhan Deniz Topuz, Sarpkan Özel
The International Journal of Neuropsychopharmacology
Bipolar Disorder and Treatment
article

The Relationship Between Manic Episodes and Serum Endocannabinoid Levels in Bipolar Disorder

Yasemin Görgülü, Ruhan Deniz Topuz, Sarpkan Özel
article en

Abstract

OBJECTIVE: Endocannabinoids are involved in biological processes relevant to mood regulation, and altered circulating levels have been reported in bipolar disorder (BD). However, serum endocannabinoid levels have not previously been examined across mania and remission within the same patients and compared with healthy controls. This study evaluated serum palmitoylethanolamide (PEA), oleoylethanolamide (OEA), 2-arachidonoylglycerol (2-AG), anandamide (AEA), and C-reactive protein (CRP) levels in patients with BD during manic episodes and remission and in healthy controls. METHODS: Fifty-one patients diagnosed with BD, manic episode, according to DSM-5-TR criteria, and 49 healthy controls were included. After discharge, 32 patients who attended outpatient follow-up visits were re-evaluated during remission. Serum PEA, OEA, 2-AG, AEA, and CRP levels were measured in all participants. Patients with BD were additionally assessed using the Young Mania Rating Scale, Hamilton Depression Rating Scale, and Positive and Negative Syndrome Scale. RESULTS: Serum PEA and OEA levels were significantly lower during manic episodes than in healthy controls. During remission, serum PEA and OEA levels did not differ significantly from those of healthy controls. In within-patient comparisons between manic episodes and remission, only serum PEA levels were significantly lower during manic episodes. CONCLUSION: This is the first study to assess serum endocannabinoid levels in patients with BD during both manic episodes and remission, together with healthy controls. PEA and OEA levels were significantly lower during mania and returned to values comparable to healthy controls during remission. These findings suggest that endocannabinoid-related mechanisms may have potential as future biomarkers and therapeutic targets in mood regulation.

The International Journal of Neuropsychopharmacology
Trakya University (TR)
Trakya Üniversitesi
Good health and well-being
Bipolar Disorder and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon